Abhishek, Swetabh and Richard transform drug discovery using machine learning!

The exponential growth of biomedical molecular data has reduced its usability, eventually slowing down the drug discovery process, making it more expensive. Elucidata’s proprietary SaaS platform - Polly, uses machine learning (ML) to accelerate the drug discovery process. The platform hosts a rich archive of over 230,000 multi-omic datasets, curated semi-automatically, with over 50,000 new datasets added each month.

Today, Elucidata has 35+ research partners from premier biopharma companies and research labs across the globe using Polly and supports the discovery programs at Pfizer, Agios Pharmaceuticals, Genentech and Yale.

A relationship built on encouragement, trust and endless support

IvyCap and Ashish have been phenomenal partners in our growth journey. It has been over a year since my first call with Vikram, and every subsequent interaction with IvyCap has deepened our relationship. As a first time founder, I have found their contributions to go far beyond their capital investment. I am thrilled to have them on our side as we continue to establish Elucidata as a market leader. We greatly value the partnership we share with Ivy Cap and look forward to the journey ahead."

- DR ABHISHEK JHA,

CO-FOUNDER & CEO

We have been associated with Ivy Cap since December last year. My team and I have worked closely with Ashish Wadhwani. His advice has been invaluable to us on countless occasions. He has guided us with his expertise and domain knowledge to face many challenges which an early age startup faces. He is a great venture capitalist and a committed member of the team who supports in navigating through critical challenges with ease. Ivy Cap has helped us with reaching out to domain experts for various needs and has been very accessible. Their market knowledge, business acumen and network have ensured the organization’s optimum growth. Special shout to the team when they extended the hand of support during the Covid -19 pandemic. We are grateful for their ongoing support."

- SWETABH PATHAK,

CO-FOUNDER & CTO

FOUNDER

Dr Abhishek Jha

Co-Founder & CEO

Before starting Elucidata, Abhishek was an early member of the platform team at Agios Pharmaceuticals and helped bring 2 first in class drugs for acute myeloid leukemia to FDA approval. He was previously trained at MIT, The University of Chicago and IIT Bombay.

Swetabh Pathak

Co-Founder & CTO

Prior to co-founding Elucidata, he has been a founding member and Product Manager at start-ups in technology and affordable STEM education and has an integrated Masters in Mathematics and Computer Science from IIT Delhi.

Their
Winning
Edge

01

Data & Technology

Our proprietary ML-based curation infrastructure powers data curation at scale, allowing us to equip scientists with harmonized, ML-Ready biomolecular data at a high velocity.

02

Processes

Our Robust curation processes include in-depth curation and review guidelines ensuring high accuracy of curation labels, that form the basis for our superior ML models.

03

Solutions

Our multi-disciplinary team of bio-informaticians, biologists, data scientists, and engineers help develop customized solutions for modern-day R&D teams to fast track their journey from data generation to insight discovery.

CLOVIA IN COVERS

IvyCap leads pre-Series A funding in health-tech firm Elucidata

Elucidata, a biomedical molecular data company, on Thursday said it has raised $5 million (Rs 36.4 crore) in its pre-Series A funding round led by IvyCap Ventures.

Know more

Elucidata Announces A $5 Million Pre-Series A Funding Round Led By IvyCap Ventures

The financing round also saw participation from Hyperplane Venture Capital and several angel investors. Elucidata will invest in go-to-market initiatives and in their data platform.

Know more

Biomedical Data Startup Elucidata Bags $16 Mn To Scale SaaS Platform Polly

The startup will use the funding to deepen product capabilities in translational drug research and allied markets

Know more